News

Antabio and GARDP join forces to identify potential next-generation antibiotics 

Geneva/Labège, 23 March 2026. The French biotech company Antabio and the GARDP Foundation (known as GARDP) today announced a joint effort to accelerate...

Antabio Announces Successful Completion of Phase 1 Clinical Study of MEM-ANT3310 for Severe Hospital Infections

The positive Phase 1 data -including good tolerability and matching PK between ANT3310 and meropenem- supports further patient studies of...

ANTABIO Announces Appointment of Dr. Erick Lelouche as Chairman of the Board

ANTABIO Raises €25 million in Series B Financing

Led by the AMR Action Fund, with subscriptions from the EIC Fund and from Antabio’s historical investors, the financing will...

Antabio Announces First Subjects Dosed in Phase 1 Clinical Trial of MEM-ANT3310, a Highly Differentiated Antibiotic for Severe Hospital Infections

Labège, France, May 25th 2023. Antabio SAS, a clinical stage biopharmaceutical company developing novel treatments for severe drug resistant bacterial...

Launch of ARPEGE, a French multidisciplinary consortium to fight antibiotic resistance through preventive, diagnostic, therapeutic and economic approaches

Led by Antabio, acting jointly with bioMérieux, Hospices Civils de Lyon, and Toulouse School of Economics, the four-year ARPEGE project...

Antabio Awarded EUR 0.9 million funding from the Occitanie Region to support the Preclinical Development of MEM-ANT3310, Antabio’s Novel Broad-Spectrum Combination Therapy Targeting WHO’s Priority Pathogens

ANT3310 is a novel, potent and specific inhibitor of bacterial Serine Beta-Lactamases (SBLs) which displays excellent inhibitory activity against both...

Antabio Receives FDA Qualified Infectious Disease Product (QIDP) Designation for MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO’s Priority Pathogens

Antabio Awarded $4.4 Million from CARB-X for the Further Development of its New Treatment for Pseudomonas aeruginosa Infections in Cystic Fibrosis Patients